Convatec Raises Outlook as New Medical Care Products Propel Growth

Convatec, the FTSE 100 medical equipment maker, has recently enhanced its medium-term financial forecasts following strong results linked to increased investment in new product offerings. This positive update comes amidst ongoing trade complexities due to US tariffs, although the company notes an exemption for products aimed at chronic illnesses.

For the financial year concluding in December, Convatec reported a group revenue of $2.4 billion, representing a rise of 4.8 per cent. This growth was propelled by robust demand across its four chronic care categories, including diabetes and Parkinson’s disease care. When excluding the InnovaMatrix wound treatment, which has suffered adverse effects from changes in US insurance payments, overall revenue growth was recorded at 6.4 per cent.

The company’s adjusted operating profit also saw an increase of 10.2 per cent, amounting to $544 million on an adjusted basis and at constant currency rates. Convatec’s forecasts for the 2026 financial year include a revenue growth projection of 5 per cent to 7 per cent, notwithstanding a potential 2 per cent headwind from InnovaMatrix.

Chief Executive Jonny Mason, who took over following the passing of former CEO Karim Bitar, emphasised that Convatec is positioned at a significantly different stage in its evolution than it was three or four years ago. The company has launched a remarkable eight new products within the last couple of years, with another eight products expected to enter the market in 2026 and 2027.

These include ConvaNiox, a wound care innovation stemming from a £45 million acquisition of an anti-infective nitric oxide technology platform. This strategic direction has generated strong market enthusiasm, demonstrated by the upward movement in Convatec’s share price, which increased by 10.4 per cent to 250.5p.

Convatec’s full-year dividend has been adjusted upwards by 13 per cent to 7.244 cents, signalling a commitment to returning value to shareholders, alongside a substantial share buyback initiative worth $300 million last year. The company is also set on expanding its geographic footprint and intends to invest in a new research and development hub in Manchester as part of a wider £500 million commitment in the UK over the next decade.

Analyst reactions to these results have been overwhelmingly positive, with many viewing the developments as a reassuring indicator of sustainable growth. Despite existing challenges in reimbursement frameworks, Convatec has maintained dependable double-digit earnings growth.